Assenagon Asset Management S.A. Avalo Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$3.0 - $10.45 $127,014 - $442,432	-42,338 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$7.57 - $21.72 $4.09 Million - $11.7 Million	-540,380 Reduced 92.73%	42,338 $31,000
Q4 2021 Feb 01, 2022	SELL	$19.68 - $28.68 $5.84 Million - $8.51 Million	-296,616 Reduced 33.73%	582,718 $991,000
Q3 2021 Oct 19, 2021	BUY	$26.16 - $40.68 $23 Million - $35.8 Million	879,334 New	879,334 $1.92 Million

34.6K

Ticker AVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,414,100
Market Cap $84.9M
Description
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.